Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model - Curtis A. Lachowiez; Joshua F. Zeidner; Jad Othman; Andy Kaempf; Seongseok Yun; Maël Heiblig; Michael Heuser; Rabia Shahswar; Rafael Madero Marroquin; Joseph M. Cannova; Andrius Žučenka; Jennifer Marvin-Peek; et al. (Journal of Clinical Oncology, 2026)